Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine and Early Recovery After Laparoscopic Colon Cancer Surgery in Elderly Patients
ChiCTR2500114176Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Shantou University Medical College
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine in colon cancer (2 arms), sponsored by The First Affiliated Hospital of Shantou University Medical College. Primary endpoints: QoR-15 score at 24 hours postoperatively, QoR-15 score at 48 hours postoperatively and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
nalbuphine
03
Conditions
colon cancer
Beyond the preview
Go deeper on ChiCTR2500114176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114176.